Biocon cancer drug wins BioSpectrum 'Product of the Year' award

Our Corporate Bureau
22 December 2007

Mumbai: Biocon Ltd, India's premier biotechnology firm, has won the BioSpectrum 'Product of the Year' award 2007, for its novel antibody-based cancer drug, BIOMAb EGFR.

BIOMAb EGFR was chosen for the award on the basis of its consistent response in clinical trials worldwide, the publications group said in a statement.

'Biocon's drug is the first of its kind to be clinically developed in India,' the statement added.

With the global launch of the drug in September 2006, the Bangalore-based firm also joined the select league of companies that have developed proprietary monoclonal antibody-based immuno-therapeutics.

Immuno-therapeutics is a new class of drugs that addresses unmet needs in oncology and autoimmune diseases like rheumatoid arthritis, psoriasis, and lupus.

The 'monoclonal antibody-based drug' treats solid tumours of epithelial origin, such as head and neck cancers.